Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Pariente
Edouard Louis

Showing results (201-210 of 364) with videos related to

Pageof 37
Sort By:
Gastroenterology|January 10, 2002
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-upFilip Baert, Alain Schmit, Geert D'Haens, et al.
Pharmacogenetics and Genomics|December 14, 2005
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's diseaseStéphanie Willot, Severine Vermeire, Marc Ohresser, et al.
The Journal of Biological Chemistry|June 16, 2012
The c-Jun N-terminal kinase (JNK)-binding protein (JNKBP1) acts as a negative regulator of NOD2 protein signaling by inhibiting its oligomerization processAurore Lecat, Emmanuel Di Valentin, Joan Somja, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|June 30, 2024
Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective TrialCarmen Monica Preda, Doina Istratescu, Maria Nitescu, et al.
Gut|October 27, 2020
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based studyNicolas Pierre, Dominique Baiwir, Vân Anh Huynh-Thu, et al.
The American Journal of Gastroenterology|July 4, 2020
Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's DiseaseNassim Hammoudi, Claire Auzolle, My-Linh Tran Minh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2018
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational studyLieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, et al.
Bulletin Du Cancer|January 23, 2015
Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancerJeanne Netter, Jacqueline Lehmann-Che, Jerome Lambert, et al.
Inflammatory Bowel Diseases|December 1, 2011
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel diseaseBenjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, et al.
Biochemical Pharmacology|January 30, 2007
Biomarker discovery for inflammatory bowel disease, using proteomic serum profilingMarie-Alice Meuwis, Marianne Fillet, Pierre Geurts, et al.
Pageof 37

Showing results (201-210 of 364) with videos related to

Sort By:
Pageof 37
Gastroenterology|January 10, 2002
Budesonide in collagenous colitis: a double-blind placebo-controlled trial with histologic follow-upFilip Baert, Alain Schmit, Geert D'Haens, et al.
Pharmacogenetics and Genomics|December 14, 2005
No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's diseaseStéphanie Willot, Severine Vermeire, Marc Ohresser, et al.
The Journal of Biological Chemistry|June 16, 2012
The c-Jun N-terminal kinase (JNK)-binding protein (JNKBP1) acts as a negative regulator of NOD2 protein signaling by inhibiting its oligomerization processAurore Lecat, Emmanuel Di Valentin, Joan Somja, et al.
Journal of Gastrointestinal and Liver Diseases : JGLD|June 30, 2024
Diet Optimization in Inflammatory Bowel Disease: Impact on Disease Relapse and Inflammatory Markers. A 1-year Prospective TrialCarmen Monica Preda, Doina Istratescu, Maria Nitescu, et al.
Gut|October 27, 2020
Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based studyNicolas Pierre, Dominique Baiwir, Vân Anh Huynh-Thu, et al.
The American Journal of Gastroenterology|July 4, 2020
Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's DiseaseNassim Hammoudi, Claire Auzolle, My-Linh Tran Minh, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 4, 2018
Dose de-escalation to adalimumab 40 mg every three weeks in patients with inflammatory bowel disease-A multicenter, retrospective, observational studyLieven Pouillon, Anne Lamoureux, Guillaume Pineton de Chambrun, et al.
Bulletin Du Cancer|January 23, 2015
Functional TP53 mutations have no impact on response to cytotoxic agents in metastatic colon cancerJeanne Netter, Jacqueline Lehmann-Che, Jerome Lambert, et al.
Inflammatory Bowel Diseases|December 1, 2011
Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel diseaseBenjamin Pariente, Guillaume Pineton de Chambrun, Roman Krzysiek, et al.
Biochemical Pharmacology|January 30, 2007
Biomarker discovery for inflammatory bowel disease, using proteomic serum profilingMarie-Alice Meuwis, Marianne Fillet, Pierre Geurts, et al.
Pageof 37